Reuters: Health
Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.
Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study
Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study
Reuters: Health
Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.
Reuters: Health
Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment